A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia

Published:2019-06-06 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Liao Dan,Wang Mengyao,Liao Yi,Li Jun,Niu Ting

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference52 articles.

1. Results of a Phase 2, open-label study of idarubicin (I), cytarabine (A) and nivolumab (Nivo) in patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS);Assi;Blood,2018

2. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation;Bashey;Blood,2009

3. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies;Berger;Clin. Cancer Res.,2008

4. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells;Blazar;J. Immunol.,1999

5. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses;Butte;Immunity,2007

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-L1 and PD-1 in immune regulation and their implications in blood cancers;Advances in Cancer Biology - Metastasis;2024-10

2. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies;Stem Cell Research & Therapy;2024-08-13

3. The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review;Pediatric pharmacology;2024-07-03

4. The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment;Frontiers in Pharmacology;2024-04-16

5. STING-activating cyclic dinucleotide-manganese nanoparticles evoke robust immunity against acute myeloid leukemia;Journal of Controlled Release;2024-04